Neuroblastoma Market Report and Forecast 2024-2032

The neuroblastoma market size is projected to grow at a compound annual growth rate (CAGR) of 2.38% during the forecast period of 2024-2032. The growth of the market is driven by the increasing incidence and prevalence of neuroblastoma, the rising awareness and funding for research and development, the availability of novel and targeted therapies, and the unmet medical needs in the field.

However, the market is also constrained by the high cost and toxicity of treatment, the lack of effective biomarkers and diagnostic tools, the heterogeneity and complexity of the disease, and the regulatory and ethical challenges in conducting clinical trials.

Neuroblastoma is a type of cancer that develops from immature nerve cells called neuroblasts. It is the most common extracranial solid tumor in children, accounting for about 7% of all pediatric cancers and 15% of all pediatric cancer deaths. The incidence of neuroblastoma is estimated to be about 11.5 cases per million children under 15 years of age, with a slight male predominance. The majority of cases (about 70%) are diagnosed before the age of 5, and about 90% before the age of 10. The prognosis of neuroblastoma varies widely depending on the age at diagnosis, the stage of the disease, the genetic and molecular features of the tumor, and the response to treatment. The 5-year survival rate ranges from over 90% for low-risk patients to less than 50% for high-risk patients.

Neuroblastoma Epidemiology

The epidemiology of neuroblastoma is influenced by several factors, such as the geographic distribution, the demographic characteristics, the environmental exposures, and the genetic and molecular variations of the disease. The epidemiology of neuroblastoma in the market can provide insights into the burden and impact of the disease, the identification of risk and protective factors, the development of prevention and screening strategies, and the estimation of the market size and potential.

The environmental exposures of neuroblastoma in the market are associated with the external and modifiable factors that can increase or decrease the risk of developing the disease. The environmental exposures of neuroblastoma in the market are not well understood and are subject to controversy and debate. However, the evidence for the role of these environmental exposures in the causation of neuroblastoma in the market is inconsistent, inconclusive, or conflicting, and requires further investigation and validation.

The genetic and molecular variations of neuroblastoma in the market are related to the internal and inherited factors that can influence the initiation, progression, and response of the disease. The genetic and molecular variations of neuroblastoma in the market are more established and recognized than the environmental exposures, and have been extensively studied and characterized. Some of the genetic and molecular variations that have been identified and validated in the pathogenesis and prognosis of neuroblastoma in the market are chromosomal aberrations, such as MYCN amplification, 1p deletion, 11q deletion, and 17q gain; gene mutations, such as ALK, PHOX2B, ATRX, and TP53; and gene expression, such as NTRK1, CD44, and NBAT1. These genetic and molecular variations of neuroblastoma in the market can be used as biomarkers and therapeutic targets and can help to stratify the patients into different risk groups and treatment protocols.

Neuroblastoma Market Drivers and Constraints

• The increasing incidence and prevalence of neuroblastoma is a major driver for the market growth. According to the American Cancer Society (ACS), about 800 new cases of neuroblastoma are diagnosed each year in the United States, and about 10,000 new cases are diagnosed each year worldwide. The incidence of neuroblastoma has increased by about 1.8% per year over the past two decades, possibly due to improved detection and diagnosis methods. The prevalence of neuroblastoma is estimated to be about 4,000 in the United States and about 50,000 worldwide, based on the 5-year survival rate.
• The rising awareness and funding for research and development is another key driver for the market growth. Neuroblastoma is recognized as a priority area for pediatric cancer research by several organizations and initiatives, such as the Children’s Oncology Group (COG), the International Neuroblastoma Research Group (INRG), the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), the Alex’s Lemonade Stand Foundation (ALSF), and the Neuroblastoma Children’s Cancer Society (NCCS). These entities provide support and collaboration for conducting basic, translational, and clinical research on neuroblastoma, as well as for developing and testing new and improved therapies. The National Cancer Institute (NCI) alone has invested D 100 million in neuroblastoma research in the past 10 years.
• The availability of novel and targeted therapies is a third key driver for the market growth. The current standard of care for neuroblastoma consists of a combination of surgery, chemotherapy, radiation therapy, stem cell transplantation, and immunotherapy. However, these treatments are often associated with severe side effects, limited efficacy, and high relapse rates. Therefore, there is a need for more effective and less toxic therapies that can target the specific molecular and genetic characteristics of the tumor. Several novel and targeted therapies are in development or have been approved for neuroblastoma, such as monoclonal antibodies, tyrosine kinase inhibitors, PARP inhibitors, histone deacetylase inhibitors, and oncolytic viruses. These therapies have shown promising results in preclinical and clinical studies, and have the potential to improve the outcomes and quality of life of neuroblastoma patients.
• The high cost and toxicity of treatment is a major constraint for the market growth. The treatment of neuroblastoma is very expensive and can impose a significant financial burden on the patients and their families. According to a study by the University of California, San Francisco (UCSF), the average cost of treating a child with high-risk neuroblastoma in the United States is D 485,000, which is more than twice the cost of treating a child with acute lymphoblastic leukemia (ALL), the most common childhood cancer. The cost of treatment can vary depending on the stage of the disease, the type and duration of therapy, the occurrence of complications and adverse events, and the availability of insurance and financial assistance. The treatment of neuroblastoma is also very toxic and can cause serious and long-term side effects, such as infections, bleeding, organ damage, growth impairment, infertility, secondary cancers, and neurocognitive deficits. These side effects can affect the physical, emotional, and social well-being of the patients and their families, and can reduce their adherence and compliance to treatment.
• The lack of effective biomarkers and diagnostic tools is another major constraint for the market growth. The diagnosis and prognosis of neuroblastoma are challenging and rely on a combination of clinical, radiological, histological, and molecular criteria. However, these criteria are not always accurate, consistent, or available, and can lead to misdiagnosis, underdiagnosis, or overdiagnosis of the disease. There is a need for more reliable and accessible biomarkers and diagnostic tools that can detect neuroblastoma early, predict the risk and outcome of the disease, monitor the response and resistance to treatment, and identify the patients who are most likely to benefit from specific therapies. Several biomarkers and diagnostic tools are under investigation or have been validated for neuroblastoma, such as urine catecholamines, serum ferritin, MYCN amplification, ALK mutations, and PET/CT scans. However, these biomarkers and diagnostic tools are not widely used in clinical practice, and their sensitivity, specificity, and utility need to be further evaluated and standardized.

Neuroblastoma Market Trends and Developments

The global neuroblastoma market is witnessing a significant evolution, driven by advances in medical research, technological innovations, and an increasing emphasis on personalized medicine. Neuroblastoma, a type of cancer that most often affects children and is characterized by tumors that develop from immature nerve cells, has been the focus of intense research efforts aimed at improving diagnosis, treatment, and survival rates. Several key trends and developments have emerged in this market such as:

1. Advances in Targeted Therapies

The development of targeted therapies represents a major advancement in the treatment of neuroblastoma. These therapies are designed to specifically attack cancer cells based on genetic characteristics without harming normal cells. The use of molecular targeted agents, such as ALK inhibitors and GD2-targeted therapies, has shown promise in improving outcomes for patients with high-risk neuroblastoma. The precision of these treatments not only enhances efficacy but also minimizes side effects, a critical consideration in pediatric oncology.

2. Immunotherapy Breakthroughs

Immunotherapy, leveraging the body's immune system to fight cancer, has made significant inroads in the neuroblastoma market. The approval and use of monoclonal antibodies, such as dinutuximab that targets GD2 on neuroblastoma cells, have markedly improved survival rates for high-risk patients. Ongoing research into novel immune checkpoint inhibitors and CAR-T cell therapies is expected to offer new hope for refractory or relapsed neuroblastoma cases.

3. Diagnostic and Prognostic Biomarkers

The identification and validation of biomarkers for neuroblastoma have enhanced both diagnostic and prognostic capabilities. Advanced genetic testing and imaging technologies enable early and accurate diagnosis of the disease, which is critical for effective treatment planning. Biomarkers are also being used to stratify patients according to risk, allowing for more tailored treatment approaches that can improve outcomes and reduce toxicity.

4. Rising Focus on Survivorship and Quality of Life

As survival rates for neuroblastoma improve, there is a growing emphasis on the long-term health and quality of life of survivors. Research is increasingly focusing on understanding and mitigating the late effects of neuroblastoma treatments, including secondary cancers, cardiovascular problems, and developmental issues. Efforts are also being made to develop interventions that support the emotional and psychological well-being of both patients and their families.

5. Increased Investment in Research and Collaboration

The neuroblastoma market is benefiting from increased investment in research and development, fueled by both public and private funding. Collaborations between pharmaceutical companies, academic institutions, and nonprofit organizations are accelerating the pace of innovation in treatment and care. These partnerships are crucial for conducting large-scale clinical trials, sharing knowledge, and translating research findings into clinical practice.

The global neuroblastoma market is at a pivotal juncture, with significant advancements in treatment and care reshaping the landscape. The focus on targeted and immunotherapeutic approaches, along with the integration of biomarkers for personalized medicine, is setting new standards in pediatric oncology. Moreover, the attention to survivorship issues underscores a holistic approach to cancer care that balances treatment efficacy with quality of life considerations. As research and collaboration continue to drive forward, the prospects for patients with neuroblastoma are brighter than ever.

Neuroblastoma Market Segmentation

Market Breakup by Diagnosis

• MIBG Scan
• Imaging
• Biopsy

Market Breakup by Treatment

• Medication
• Surgery
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplantation
• Immunotherapy
• Monoclonal Antibody Treatment

Market Breakup by Age Group

• Infants
• Children
• Adolescents

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Surgical Centers
• Diagnostic Centers
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• China

Neuroblastoma Market Competitor Landscape

The competitive landscape of the global neuroblastoma market is characterized by the active participation of major pharmaceutical and biotechnology companies, alongside key players in diagnostics and biologics. These entities are engaged in a variety of market activities, including mergers and acquisitions, collaborative research initiatives, the introduction of new products, and strategic partnerships aimed at advancing neuroblastoma treatment and diagnostic solutions. Key players in this dynamic market include Eli Lilly and Company, Bayer AG, GE Healthcare, Beckman Coulter Inc., bioMerieux, BD Biosciences, Lonza Biologics Ltd., Sanofi S.A., Pfizer Inc., Cellectar Biosciences, Baxter International Inc., APEIRON Biologics AG, United Therapeutics Corporation, Sartorious AG, and MacroGenics, Inc. These companies are at the forefront of innovation in neuroblastoma care, driving progress through extensive research and development efforts, as well as through forging alliances and exploring synergies that can enhance treatment efficacy and improve patient outcomes.


This product will be delivered within 5-7 business days.